These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 20802534

  • 1. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
    Liu W, Xin H, Eckert DT, Brown JA, Gnarra JR.
    Oncogene; 2011 Jan 06; 30(1):21-31. PubMed ID: 20802534
    [Abstract] [Full Text] [Related]

  • 2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.
    Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293
    [Abstract] [Full Text] [Related]

  • 3. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
    Moch H.
    Pathologe; 2008 Nov 01; 29 Suppl 2():149-52. PubMed ID: 18751708
    [Abstract] [Full Text] [Related]

  • 4. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER.
    Hum Mol Genet; 2001 May 01; 10(10):1029-38. PubMed ID: 11331613
    [Abstract] [Full Text] [Related]

  • 5. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
    Kapitsinou PP, Haase VH.
    Cell Death Differ; 2008 Apr 01; 15(4):650-9. PubMed ID: 18219317
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
    Zhou L, Yang H.
    PLoS One; 2011 Apr 01; 6(9):e23936. PubMed ID: 21949687
    [Abstract] [Full Text] [Related]

  • 9. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K, Cartwright E, Freund S, Bycroft M, Buchberger A.
    J Biol Chem; 2009 Apr 17; 284(16):10514-22. PubMed ID: 19228690
    [Abstract] [Full Text] [Related]

  • 10. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
    Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD.
    Cancer Res; 2002 Jun 01; 62(11):3014-9. PubMed ID: 12036906
    [Abstract] [Full Text] [Related]

  • 11. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER.
    Oncogene; 2005 Jun 30; 24(28):4549-58. PubMed ID: 15824735
    [Abstract] [Full Text] [Related]

  • 12. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ.
    Nature; 1999 May 20; 399(6733):271-5. PubMed ID: 10353251
    [Abstract] [Full Text] [Related]

  • 13. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
    Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, Ohh M.
    Mol Cell Biol; 2004 Apr 20; 24(8):3251-61. PubMed ID: 15060148
    [Abstract] [Full Text] [Related]

  • 14. The von Hippel-Lindau protein forms fibrillar amyloid assemblies that are mitigated by the anti-amyloid molecule Purpurin.
    Kumar V, Kaushik V, Kumar S, Levkovich SA, Gupta P, Laor Bar-Yosef D, Gazit E, Segal D.
    Biochem Biophys Res Commun; 2024 Jan 01; 690():149250. PubMed ID: 38039781
    [Abstract] [Full Text] [Related]

  • 15. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer.
    Chakraborty AA.
    Semin Cancer Biol; 2020 Dec 01; 67(Pt 2):34-42. PubMed ID: 32209418
    [Abstract] [Full Text] [Related]

  • 16. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
    He X, Wang J, Messing EM, Wu G.
    Oncogene; 2011 Feb 03; 30(5):535-47. PubMed ID: 20871634
    [Abstract] [Full Text] [Related]

  • 17. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA, Ohh M.
    Am J Nephrol; 2004 Feb 03; 24(1):1-13. PubMed ID: 14654728
    [Abstract] [Full Text] [Related]

  • 18. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [Abstract] [Full Text] [Related]

  • 19. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER.
    Oncogene; 2001 Aug 16; 20(36):5067-74. PubMed ID: 11526493
    [Abstract] [Full Text] [Related]

  • 20. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
    Turcotte S, Desrosiers RR, Beliveau R.
    Am J Physiol Renal Physiol; 2004 Feb 16; 286(2):F338-48. PubMed ID: 14583436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.